Project Name: Guy’s St Thomas’ Breast Cancer service development collaborative working

Project Summary:

The Collaborative Working Project (CWP) aims to free up capacity within the breast cancer (BC) pathway with the addition of dedicated new roles:-

“Systemic Anti-Cancer Therapy Lead Advanced Clinical Practitioner (SACT LACP) band 8B for 18 months with 15 months clinical activity 

and Systemic Anti-Cancer Therapy Lead Advanced Clinical Practitioner (SACT NMP) band 8A 0.6 whole time equivalent (WTE) Band for 15 months 14 months  clinical activity.

These roles will be responsible for designing and delivering a streamlined oral Systemic Anti-Cancer Therapy (SACT) pathway. This includes developing pre-treatment education, optimising patient self-management, and providing support for disease management, pre-assessment, review, education, and follow-up for breast cancer patients eligible for oral SACT therapies. Additionally, the roles will involve implementing the newly developed digital learning resources, coordinating and leading virtual oral Non-Medical Prescriber (NMP) clinics, introducing E-PROMS/Careology, and developing metrics to inform a business case for the sustainability of these positions.

Expected Benefits:

Benefits to Patients 

  • Increased access to equitable and consistent and standardised care 
  • Increased access to education on BC and treatments to improve adherence and consequently improve patients' outcomes, supported by a personalised care plan. 
  • Improved patient satisfaction and reduced waiting time (to access overbooked clinics)
  • Reduced patient in person attendances
  • Reduce unplanned medical reviews and admissions

Benefits to NHS

  • Increase the overall quality of care and improve equity of access to specialist care for patients with BC requiring treatment initiation, evaluation, and monitoring.
  • Improved clinician experiences
  • Provision of subject matter expertise to educate other members of the clinical team on treatment options.
  • Provide a single point of contact for patients, thereby reducing the potential for unplanned calls being received by the wider clinical team.
  • Free up consultant capacity for clinical activities that are unique to their skillset.

Benefits to Novartis

  • Better understanding of overall HCP and patient needs
  • Optimal use of medicines in line with local/national guidance (including Novartis medicines) in appropriate patients.
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisations

Start Date & Duration: April 2025 for 24 months

FA-11387364 | March 2025